Race Receives $4.0m R&D Tax Refund for Financial Year 2023
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The refund, amounting to a substantial sum, is part of the Federal Government’s R&D Tax Incentive scheme aimed at encouraging investment in innovation. The CEO highlighted the importance of this funding in advancing the clinical development of their lead asset, bisantrene, in the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Racura Oncology
- December 2023 Preclinical & Clinical Program Update
- Bonus Options Prospectus
- Updated Strategy and Investor Presentation
- Dr Daniel Tillett appointed CEO of Race Oncology
- RC220 Meets Quality Specifications
Later from Racura Oncology
- S&P DJI Announces March 2024 Quarterly Rebalance
- Bisantrene shows potent anticancer activity in AML models
- RC220 cGMP Manufacturing Complete
- Quarterly Activity Report & Appendix 4C
- Bisantrene with Decitabine Enhances Cancer Cell Killing
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology